Data on Drug Delivery Systems Reported by Researchers at University of Wisconsin School of Medicine and Public Health (Intrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic)
By a News Reporter-Staff News Editor at Drug Week Current study results on Drugs and Therapies - Drug Delivery Systems have been published. According to news reporting originating from Madison, Wisconsin, by NewsRx correspondents, research stated, "The development of new image-guided drug delivery tools to improve the therapeutic efficacy of chemotherapeutics remains an important goal in nanomedicine. Using labeling strategies that involve radioelements that have theranostic pairs of diagnostic positron-emitting isotopes and therapeutic electron-emitting isotopes has promise in achieving this goal and further enhancing drug performance through radiotherapeutic effects."
Financial supporters for this research include National Cancer Institute, U.S. Department of Energy, American Cancer Society, University of Wisconsin-Madison (see also Drugs and Therapies - Drug Delivery Systems).
Our news editors obtained a quote from the research from the University of Wisconsin School of Medicine and Public Health, "The isotopes of radioarsenic offer such theranostic potential and would allow for the use of positron emission tomography (PET) for image-guided drug delivery studies of the arsenic-based chemotherapeutic arsenic trioxide (ATO). Thiolated mesoporous silica nanoparticles (MSN) are shown to effectively and stably bind cyclotron-produced radioarsenic. Labeling studies elucidate that this affinity is a result of specific binding between trivalent arsenic and nanoparticle thiol surface modification. Serial PET imaging of the in vivo murine biodistribution of radiolabeled silica nanoparticles shows very good stability toward dearsenylation that is directly proportional to silica porosity. Thiolated MSNs are found to have a macroscopic arsenic loading capacity of 20 mg of ATO per gram of MSN, sufficient for delivery of chemotherapeutic quantities of the drug."
According to the news editors, the research concluded: "These results show the great potential of radioarsenic-labeled thiolated MSN for the preparation of theranostic radiopharmaceuticals and image-guided drug delivery of ATO-based chemotherapeutics."
For more information on this research see: Intrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic. Acs Applied Materials & Interfaces, 2017;():. (American Chemical Society - www.acs.org; Acs Applied Materials & Interfaces - www.pubs.acs.org/journal/aamick)
The news editors report that additional information may be obtained by contacting P.A. Ellison, Dept. of Medical Physics and Dept. of Radiology, University of Wisconsin School of Medicine and Public Health , Madison, Wisconsin 53726, United States. Additional authors for this research include F. Chen, S. Goel, T.E. Barnhart, R.J. Nickles, O.T. DeJesus and W. Cai.
Keywords for this news article include: Madison, Arsenic, Wisconsin, Nanoparticle, United States, Nanotechnology, Drugs and Therapies, Drug Delivery Systems, Emerging Technologies, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC